2019 ATLANTA PRECISIONONCOLOGY SYMPOSIUM

EXHIBITOR PROSPECTUSEXHIBITOR PROSPECTUS

SATURDAY, FEBRUARY 9, 2019InterContInental BuCkhead atlanta

Breast/Genitourinary/Lung

IntroduCtIon & ratIonale

We invite you to join us for a one-day continuing education program that will focus on current approaches to integrating and applying precision medicine into managing patients with breast, lung, and genitourinary cancers. Precision medicine, also known as personalized or individualized medicine, has been a longstanding dream for cancer patients and doctors. The last decade has brought amazing progress on this front. Thanks to the advent of precision medicine and the growing list of targeted therapies that have revolutionized the management of liquid and solid tumors, doctors can now rationally select treatments for cancer patients.

With progress in precision oncology comes complexity of patient care. Identification and validation of actionable targets and their variants, understanding post-target intracellular signaling pathway, selection of optimal targeted agent for first-line treatment, complexity of characterizing mechanisms of cancer cell resistance, and selection of alternative targeted agents to be used in second-line treatment and beyond, are just a few of the complexities of precision medicine. As such, oncologists should not only “want” to know more about the topic, they actually “need” to know more, given the rapid evolving reality of cancer patient care.

The inaugural Atlanta Precision Oncology Symposium (APOS) is a pioneering educational program designed to present the complexities of oncology precision medicine in an organized, simplified, friendly fashion, so that they can be understood and properly applied to clinical medicine. Experts in the fields of breast, lung, and genitourinary cancers will share the latest precision medicine advances and practical integration into the clinic.

The program will be of interest to those practicing in the context of academia, as well as those in the community oncology environ. Practitioners attending APOS will emerge from the program updated on recent data and armed with new tools to help them integrate precision medicine approaches into their daily clinical practice.

This meeting has been planned and will be implemented in accordance with the Essential Areas and Policies of the ACCME. CME, CNE, and pharmacy credit will also be offered.

www.ATLprecisiononcology.com

Breast/Genitourinary/LunG

2019 ATLANTA PRECISION ONCOLOGY SYMPOSIUM SATURDAY, FEBRUARY 9, 2019InterContInental BuCkhead atlanta

EXHIBITOR PROSPECTUSwww.ATLprecisiononcology.com

ProGraM aGenda TIME TOPIC SPEAKER

7:15-8:00 am Optional Breakfast Symposium: TMB High and the Impact It has on the Selection of Patients With Advanced Cancer for Immunotherapy

To be announced

8:00-8:15 am Opening Remarks Rodolfo E. Bordoni, MD (Chair)

Session 1: LUNG CANCER Moderator: Gregory J. Riely, MD, PhD

8:15-8:40 am 2019 State of the Art Management of ALK-positive NSCLC Christine M. Lovly, MD, PhD

8:40-9:05 am Emerging Genomic and Proteomic Biomarkers to Maximize Benefit of PD-1/PD-L1 Axis Inhibition in Lung Cancer

Benjamin Levy, MD

9:05-9:30 am Targeting MET Exon 14 Alterations in Metastatic NSCLC with Progression After Platinum-based Chemotherapy

Gregory J. Riely, MD, PhD

9:30-10:00 am Q&A Session

10:00-10:15 am Break

Session 2: GENITOURINARY CANCERS Moderator: Maha H. A. Hussain, MD, FACP, FASCO

10:15-10:40 am Targeting DNA Repair in Metastatic Castration-resistant Prostate Cancer: Is it Time Yet?

Maha H. A. Hussain, MD, FACP, FASCO

10:40-11:05 am Novel Agents, Including Anti-FGFR and ADC Targeting Nectin, in Advanced Urothelial Cancer

Jonathan E. Rosenberg, MD

11:05-11:30 am Emerging Data on the Role of Checkpoint Inhibitors in Urothelial Carcinoma

Daniel Petrylak, MD

11:30-12:00 pm Q&A Session

LUNCH AND LEARN

12:15-12:20 pm Introduction Rodolfo E. Bordoni, MD

12:20-1:00 pm NCI and the Precision Medicine Initiative® (Lung-MAP, ALCHEMIST, NCI-MPACT, and NCI-MATCH): Early Data and Lessons Learned

Vassiliki Papadimitrakopoulou, MD

1:05-1:25 pm Q&A Session

Session 3: BREAST CANCER Moderator: Joseph A. Sparano, MD

1:25-1:50 pm Genetics and Genomics in Studying Breast Cancer Disparities Lisa Newman, MD, MPH

1:50-2:15 pm Novel Drugable Pathways in Triple Negative Breast Cancer Senthil Damodaran, MD, PhD

2:15-2:40 pm Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer

Joseph A. Sparano, MD

2:40-3:10 pm Q&A Session

3:10-3:20 pm Break

SPECIAL PLENARY SESSION

3:20-3:45 pm Current Precision Oncology Status in the Local Community: Incentives and Obstacles

To be announced

3:45-4:00 pm Q&A Session

4:00 pm Closing Remarks Rodolfo E. Bordoni, MD (Chair)

Breast/Genitourinary/LunG

2019 ATLANTA PRECISION ONCOLOGY SYMPOSIUM SATURDAY, FEBRUARY 9, 2019InterContInental BuCkhead atlanta

EXHIBITOR PROSPECTUSwww.ATLprecisiononcology.com

Rodolfo E. Bordoni, MD (Chair) Georgia Cancer Specialists Atlanta, GA

Senthil Damodaran, MD, PhD The University of Texas MD Anderson Cancer Center Houston, TX

Maha H. A. Hussain MD, FACP, FASCO Feinberg School of Medicine Northwestern University Chicago, IL

Benjamin Levy, MD Johns Hopkins School of Medicine Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Baltimore, MD

Christine M. Lovly, MD, PhD Vanderbilt Ingram Cancer Center Vanderbilt University Medical Center Nashville, TN

Lisa Ann Newman, MD, MPH, FASCO Weill Cornell Medicine-New York Presbyterian Hospital Network New York, NY

Vassiliki Papadimitrakopoulou, MD University of Texas MD Anderson Cancer Center Houston, TX

Daniel Petrylak, MD Yale Cancer Center New Haven, CT

Gregory J. Riely, MD, PhD Memorial Sloan Kettering Cancer Center New York, NY

Jonathan E. Rosenberg, MD Memorial Sloan Kettering Cancer Center New York, NY

Joseph A. Sparano, MD Albert Einstein College of Medicine and Montefiore Medical Center New York, NY

FaCultY

The overarching goal of the symposium is to identify conditions, and specific situations within a condition, where targeted therapy applies, thereby addressing the need for more education on functional targets (validated or controversial), targeted agents (in the market or coming up), and predictive markers of efficacy to targeted therapy.

At the conclusion of this educational activity, participants should be able to:

1. Navigate the management of ALK-positive, advanced NSCLC, from targeted to chemo to immunotherapy

2. Identify emerging biomarkers to maximize the benefit of PD-1/PD-L1 inhibition in lung cancer

3. Describe targetable MET Exon 14 alterations in progressive, metastatic NSCLC

4. Identify new patient populations with unique targets in the management of GU malignancies

5. Discuss how genetics and genomics factor into breast cancer disparities

6. Identify novel drugable pathways in triple-negative breast cancer

7. Discuss utilization of a 21-gene expression assay in adjuvant chemotherapy treatment decisions for early-stage breast cancer

8. Discuss incentives and obstacles to applying precision medicine in the community setting

learnInG oBJeCtIVeS

Breast/Genitourinary/LunG

2019 ATLANTA PRECISION ONCOLOGY SYMPOSIUM SATURDAY, FEBRUARY 9, 2019InterContInental BuCkhead atlanta

EXHIBITOR PROSPECTUSwww.ATLprecisiononcology.com

InterContinental Buckhead Atlanta 3315 Peachtree Rd NE Atlanta, GA 30326

Phone: (404) 946-9000

Reservations: (877) 834-3613

Attendee Profile

All Atlanta Precision Oncology Symposium attendees will have access to the exhibit hall. This educational program is directed toward medical oncologists, radiation oncologists, breast and thoracic surgeons, urologists, pulmonolo-gists, and pathologists; fellows, nurse practitioners, physician assistants, nurses, pharmacists, nurse navigators, and researchers are also invited to attend.

Why Exhibit at Atlanta Precision Oncology Symposium?

As an exhibitor, you are a vital component to the success of the inaugural Atlanta Precision Oncology Symposium, and the planning team is committed to providing you with a forum to present your products and services to the APOS audience. This year’s meeting will offer exclusive opportunities to exhibitors. Specifically, exhibitors will have valuable opportunities to engage key opinion leaders in oncology, identify potential new business opportunities, connect with colleagues, increase visibility of their brand, and market any new products or services.

Who should join us as an exhibitor at APO 2019?

• Pharmaceutical Companies • Diagnostics Companies • Biomarker Testing Manufacturers • Professional Associations • Healthcare Facilities

An Exhibit Table ($2,500) includes:

• One table-top exhibit space • Two complimentary registrations

Exhibit space is limited and cannot be guaranteed until full payment is received. All exhibit applications will be pro-cessed on a first-come, first-serve basis. APOS planning staff reserves the right to rearrange the floor plan and/or relocate assigned spaces. The exhibit hall will be open until 3:20 pm.

Venue

eXhIBItor InForMatIon

Breast/Genitourinary/LunG

2019 ATLANTA PRECISION ONCOLOGY SYMPOSIUM SATURDAY, FEBRUARY 9, 2019InterContInental BuCkhead atlanta

EXHIBITOR PROSPECTUSwww.ATLprecisiononcology.com

SuPPort oPPortunItIeS

APO offers organizations the opportunity to be spon-sors of the event, at the levels of Diamond, Gold, Silver, or Bronze. To become a sponsor at any of these levels, please visit www.ATLprecisiononcology.com.

DIAMOND ($15,000)

• Eight (8) complimentary full-conference registrations

• Two (2) complimentary table top displays at symposium

• Preferential assistance with meeting space

• Acknowledgement on slide (during breaks)

• On-site signage

• Logo and sponsorship level recognition on

APO website

• List of attendees

GOLD ($12,500)

• Six (6) complimentary full-conference registrations

• One (1) complimentary table top display at symposium

• Acknowledgement on slide (during breaks)

• On-site signage

• Logo and sponsorship recognition on APO website

• List of attendees

Please visit www.ATLprecisiononcology.com to register.For more information, contact Georgea Polizos at (404) 290-2483 or gpolizos@phillipsgilmore.com

SILVER ($10,000)

• Four (4) complimentary full-conference registrations

• One (1) complimentary table top display at symposium

• Acknowledgement on slide (during breaks)

• On-site signage

• Logo and sponsorship recognition on APO website

BRONZE ($7,500)

• Two (2) complimentary full-conference registrations

• One (1) complimentary table top display at symposium

• Acknowledgement on slide (during breaks)

• On-site signage

• Name recognition on APO website

ADDITIONAL SUPPORT OPPORTUNITIES:

• Wireless Internet Access ($3,000)

• Refreshment Break ($2,000)

• Continental Breakfast ($2,000)

• Buffet Lunch ($3,000)

• Morning Symposium ($5,000)